BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Viatronix, Inc V3D®-Colon Software Exclusively Used in Another Important Clinical Trial on CT Colonography


6/12/2013 9:33:25 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

STONY BROOK, N.Y., June 12, 2013 /PRNewswire/ -- Viatronix Incorporated announced today that its dedicated CT Colonography (CTC) softwareV3D-Colon was exclusively used in another important clinical study relating to colorectal cancer screening. The latest CTC study, "Assessment of volumetric growth rates of small colorectal polyps with CT colonography: a longitudinal study of natural history" (Lancet Oncology, online June 7, 2013), tracked polyp growth in 243 patients over an eight year period.

For the first time there is direct evidence and statistical proof that colorectal polyp-volume growth over time delivers true clinical value for identifying advanced adenomas. The advanced adenoma polyp is the primary target in colorectal cancer screening. When an advanced adenoma polyp is identified and removed the likelihood of colorectal cancer developing is significantly reduced.

"Viatronix is extremely proud to have been an integral part of such an important trial," said Zaffar Hayat, President and CEO of Viatronix Incorporated.  He went on to say, "The Viatronix platform has been the software of choice in several landmark clinical trials over the past ten years. V3D-Colon's user friendly interface, diagnostic tools and short read times backed by strong clinical validation make it the system of choice for leading experts."

This study once again proves CTC is effective for colon cancer screening.

Screening CTC is currently reimbursed by many insurance carriers and coverage is mandated in approximately 30 States.  Presently there is legislation in Congress for CMS/Medicare to cover the cost for this invaluable colorectal cancer screening exam.

About Viatronix

Viatronix, Inc. located in Stony Brook, New York, U.S.A. is a leading innovator of non-invasive 2D/3D medical imaging and diagnostic software that enables physicians to interactively view vital organs and anatomical structures within the human body.  The Company's V3D® technology software solutions include Viatronix V3D-Colon, V3D-Cardiac, V3D-Vascular, V3D-Calcium Scoring, and V3D-Explorer.,

To learn more, call us at 1-866-887-4636 or visit: www.viatronix.com.

SOURCE Viatronix Inc.



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES